Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Ravidasvir and Danoprevir/r in Healthy Volunteers
NCT03288636Phase 1Completed
- Sponsor
- Ascletis Pharma Inc.
- Start
- Aug 2017
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ravidasvir in hepatitis C (HCV) (2 arms), sponsored by Ascletis Pharma Inc. Primary endpoint: Incidence of adverse events at 40 days. Started Aug 2017; status: completed.
02
Drugs
ravidasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03288636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03288636.